Literature DB >> 26289128

Effects of denosumab on peripheral lymphocyte subpopulations.

Maurizio Rossini1, Ombretta Viapiana2, Silvano Adami2, Luca Idolazzi2, Francesco Ghellere2, Gaia Tripi2, Riccardo Ortolani3, Roberta Zanotti4, Davide Gatti2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26289128     DOI： 10.1007/s12020-015-0723-6

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


× No keyword cloud information.
  18 in total

1.  Effects of the anti-inflammatory drug salsalate on bone turnover in type 2 diabetes mellitus.

Authors:  Mishaela R Rubin; Allison B Goldfine; Donald J McMahon; Daniel S Donovan; Serge Cremers; Elzbieta Dworakowski; Ernst J Schaefer; Steven E Shoelson; Shonni J Silverberg
Journal:  Endocrine       Date:  2015-02-01       Impact factor: 3.633

Review 2.  Do RANKL inhibitors (denosumab) affect inflammation and immunity?

Authors:  S Ferrari-Lacraz; S Ferrari
Journal:  Osteoporos Int       Date:  2010-06-23       Impact factor: 4.507

3.  Inhibition of osteoclast function reduces hematopoietic stem cell numbers in vivo.

Authors:  Stefania Lymperi; Adel Ersek; Francesca Ferraro; Francesco Dazzi; Nicole J Horwood
Journal:  Blood       Date:  2010-12-03       Impact factor: 22.113

Review 4.  Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab.

Authors:  David L Lacey; William J Boyle; W Scott Simonet; Paul J Kostenuik; William C Dougall; John K Sullivan; Javier San Martin; Roger Dansey
Journal:  Nat Rev Drug Discov       Date:  2012-05       Impact factor: 84.694

5.  Osteoclast activity modulates B-cell development in the bone marrow.

Authors:  Anna Mansour; Adrienne Anginot; Stéphane J C Mancini; Claudine Schiff; Georges F Carle; Abdelilah Wakkach; Claudine Blin-Wakkach
Journal:  Cell Res       Date:  2011-02-15       Impact factor: 25.617

6.  Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.

Authors:  Henry G Bone; Michael A Bolognese; Chui Kin Yuen; David L Kendler; Huei Wang; Yu Liu; Javier San Martin
Journal:  J Clin Endocrinol Metab       Date:  2008-04-01       Impact factor: 5.958

7.  A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women.

Authors:  Pirow J Bekker; Donna L Holloway; Amy S Rasmussen; Robyn Murphy; Steven W Martin; Philip T Leese; Gregory B Holmes; Colin R Dunstan; Alex M DePaoli
Journal:  J Bone Miner Res       Date:  2004-03-01       Impact factor: 6.741

Review 8.  Role of T cells in the modulation of PTH action: physiological and clinical significance.

Authors:  Roberto Pacifici
Journal:  Endocrine       Date:  2013-06-02       Impact factor: 3.633

Review 9.  Skeletal and extraskeletal actions of denosumab.

Authors:  Kathrin Sinningen; Elena Tsourdi; Martina Rauner; Tilman D Rachner; Christine Hamann; Lorenz C Hofbauer
Journal:  Endocrine       Date:  2012-05-13       Impact factor: 3.633

10.  Osteoclasts are dispensable for hematopoietic stem cell maintenance and mobilization.

Authors:  Kana Miyamoto; Shigeyuki Yoshida; Miyuri Kawasumi; Kazuaki Hashimoto; Tokuhiro Kimura; Yuiko Sato; Tami Kobayashi; Yoshiteru Miyauchi; Hiroko Hoshi; Ryotaro Iwasaki; Hiroya Miyamoto; Wu Hao; Hideo Morioka; Kazuhiro Chiba; Takashi Kobayashi; Hisataka Yasuda; Josef M Penninger; Yoshiaki Toyama; Toshio Suda; Takeshi Miyamoto
Journal:  J Exp Med       Date:  2011-10-17       Impact factor: 14.307
View more
  1 in total

Review 1.  Pulling RANK on Cancer: Blocking Aire-Mediated Central Tolerance to Enhance Immunotherapy.

Authors:  Maureen A Su; Mark S Anderson
Journal:  Cancer Immunol Res       Date:  2019-06       Impact factor: 11.151
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.